fda

Erez Capital Announces Additional Venture Partners

Erez Capital, a emerging venture capital fund investing in disruptive technologies, is thrilled to announce the addition of new Venture Partners. Boston, Massachusetts, United States - August 3rd, 2023 — Erez Capital, a emerging venture capital fund investing in disruptive technologies, is thrilled to announce its addition of 40 Venture Partners to join the fund. These new partners will play an important role in the quickly developing artificial intelligence ecosystem - specifically in the proptech, medtech and fintech sectors. “This fund and its investments will represent the consensus of experts,

Renowned Physician-Pharmacist Dr. Anita Gupta joins Erez Capital, Bringing Healthcare Innovation Expertise on Board.

Boston, MA, July 26th, 2023-- Erez Capital is proud to announce the addition of Dr. Anita Gupta to its esteemed team of Venture Partners. Dr. Gupta, a global leader in healthcare innovation, is renowned for her ground-breaking contributions to the medical field and her exceptional expertise in anesthesiology and pain management. With an illustrious career and a portfolio of remarkable accomplishments, Dr. Anita Gupta has made a significant impact on healthcare innovation and patient advocacy. As a World Economic Forum Member Expert, she has been recognized as one of the

Sacrix LLC To Be Issued A 3D Porous Patent On Its Threaded Implant And Lateral-Oblique Sacroiliac Joint Fusion Technique On September 28th, 2021

Sacrix New 3D Porous Sacroiliac Joint (SIJ) Threaded Implant For Percutaneous Minimally Invasive SI Joint Fusion the patent includes a device claim of our threaded implant with the fusion channel; also an embodiment with a 3D porous structure MALDEN, Mass. (PRWEB) September 18, 2021 Vito Lore, the VP of innovations at KICVentures Group, said "the patent includes a device claim of our threaded implant with the fusion channel; also an embodiment with a 3D porous structure". "Clinically the 3D porous structure is expected to enhance the threaded implant's performance in

New Lab Studies Suggest InBios COVID-19 POC Antigen Detection Test Will Detect Delta Variant

SCoV-2 Ag Detect Rapid Test SEATTLE (PRWEB) August 22, 2021 InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that laboratory studies suggest its SCoV-2 Ag Detect Rapid Test will detect the Delta variant (lineage B.1.617.2), which is responsible for a rapid rise of infections and deaths in the US and around the world. Initial studies suggest that InBios’ point-of-care antigen test will detect the Delta variant at rates similar to the USA-WA1-2020 isolate that was used to develop the assay. “Having a rapid